<DOC>
	<DOCNO>NCT01416571</DOCNO>
	<brief_summary>This trial ass immunogenicity safety GSK Biologicals ' vaccine GSK1557484A , prepare old concentrated monobulk material , adult age 18 64 year , administer 5 year follow production .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Monovalent Pandemic H5N1 Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A male female 18 64 year age time first vaccination . Written inform consent obtain subject . Stable general health establish medical history clinical examination enter study . Subject access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception 2 month completion vaccination series . Previous vaccination time H5N1 vaccine . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Presence significant acute chronic , uncontrolled medical psychiatric illness . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject unable/unlikely provide accurate safety report . Presence temperature ≥ 38.0ºC , acute symptom great `` mild '' severity schedule date first dose . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Receipt systemic glucocorticoid within 1 month prior study enrolment , cytotoxic immunosuppressive drug within 6 month study enrolment . Topical , intraarticularly inject , inhaled glucocorticoid , topical calcineurin inhibitor imiquimod allow . Receipt immunoglobulins and/or blood product within 3 month first study vaccination plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior dose , eligible . Persons receive prophylactic antiplatelet medication , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Administration inactivate live , attenuated seasonal influenza vaccine within 14 day first study vaccine dose , vaccine ( ) foreseen study protocol within 30 day first study vaccine dose . Planned administration vaccine ( ) foreseen study protocol completion Day 42 visit . Any known suspected allergy constituent influenza vaccine , history severe reaction previous influenza vaccination . Known pregnancy positive urine betahuman chorionic gonadotropin test result prior first study vaccine dose . Lactating nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>H5N1</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>influenza infection</keyword>
	<keyword>GSK1557484A</keyword>
</DOC>